Isopeptidase-Fluorogenic Assays

ZediXcite Fluorogenic TG2-Assay Kit

Isopeptidase-activity based TG2 assay (330/418 nm)

1 Kit 600 € available

Art. No. F014
Assay principle TISSUE TRANSGLUTAMINASE (TG2) cleaves a dark quenching molecule from the side chain of TG2 specific peptide A163 incorporating glycine methyl ester. Subsequently, the fluorescence of an N-terminal coupled dye increases and can be monitored (excitation wavelength 330 nm; emission wavelength 418 nm).
Reagents in the kit (1) SUBSTRATE REAGENT (SR): 2 x 23 μL TG2 specific peptide A163 (DMSO solution).
(2) BUFFER REAGENT (BR): 2 x 18 mL TRIS buffer pH 7.5 containing calcium chloride, sodium chloride, glycine methyl ester (lyophilizate).
(3) DILUTION BUFFER (DB): 1 x 18 mL TRIS buffer pH 8.1 containing sodium chloride, EDTA, DTT (lyophilizate).
Equipment The ZediXcite Fluorogenic TG2-Assay Kit (F014) can be used in fluorescence microplate readers using microplates as well as in standard fluorescence spectrophotometers with cuvettes. Refer to the instructions of the manufacturer.
Application Determination of TISSUE TRANSGLUTAMINASE (TG2) activity, specific and sensitive. Suitable for measurements of 1.25 nM to 10 nM (100 ng/mL to 780 ng/mL) of TG2.
Reference(s) Parameswaran, K.N. et al. J. Biol. Chem. 1997, 272, 10311.
Oertel, K. et al. Anal. Biochem. 2007, 367, 152.


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageSuccessful ISO9001:2015 recertification
  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis


  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering


  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy